-Aiming to become an agile, best-in-class global pharmaceutical company-
Osaka, Japan, July 31, 2015 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it has published the Annual Report 2015, which offers a thorough look at the company's business results and Corporate Social Responsibility accomplishments in fiscal 2014, as well as strategies for fiscal 2015 and beyond.
Christophe Weber, President and Chief Executive Officer, commented, "Since I joined the company in April 2014, our focus has been to become an agile, best-in-class global pharmaceutical company in every activity. Keeping the values of Takeda-ism (Integrity: Fairness, Honesty and Perseverance) as our foundation, we focused on the priorities of Patient (put the patient at the center), Trust (build trust with society), Reputation (reinforce our reputation), and Business (develop the business) -- in that order. Fiscal 2015 will be an extremely important year for Takeda, and we will achieve organic growth by increasing our focus on growth drivers, namely the core therapeutic areas of Gastroenterology (GI) and Oncology, and our Value Brands (branded generics and over-the-counter products) in Emerging Markets."
Takeda will continue to engage in dialogue with all stakeholders to gain their deeper understanding, and as a pharmaceutical company committed to improving people’s lives, will also stay focused on its mission, “We strive towards better health for people worldwide through leading innovation in medicine.”
The digital version of Takeda's Annual Report 2015 is online at:
Located in Osaka, Japan, Takeda (TYO: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Internal Disclaimer Body